Today, biomaterial-based solutions play an important role in clinical applications.

They can be implemented e.g. astissue repair scaffolds or replace elements of damaged body parts. As these biomaterials directly interact with the human body, unforseen adverse reactions can occur.

PANBioRA will develop a tool to better assess a patient-specific immune reaction to biomaterials and thus allow improved clinical outcomes.

Components of the PANBioRa biomaterial risk assessment system

ANTIBODY TESTING

Patient-specific interactions between biomaterials and the immune system will be assessed using the ground-breaking Mimotope Variation Analysis technology.

BIOMATERIAL TESTING

Biochemical responses of cells to the presence of biomaterials will be monitored in real time and by integrated biosensors. In addition, PANBioRA includes cytotoxicity and genotoxicity tests with microscopic real-time monitoring capacities

CELL TESTING

Real-time electrochemical sensing will be used to determine the cellular response to a given biomaterial. A set of cytokines released to the extracellular environment will be used as biomarkers to assess the cell response to different biomaterials.

ORGAN ON A CHIP

Respiratory epithelium, gut and liver tissues will be miniaturized into organoids on chip to allow the determination of possible systemic and target organ-specific effects in both healthy and disease conditions.

Components of the PANBioRA biomaterial risk assessment system

SIMULATIONS

Potential risks that are difficult to assess experimentally – such as explosion hazards or full-scale biomaterial/microbiota interactions - will be covered by simulations developed within the project.

DATA ANALYSIS

The readouts of the modules will be fed into a model developed within PANBioRA using known biocompatible and hazardous materials to provide a quantitative risk assessment.